Print Page   |   Contact Us   |   Sign In   |   Become a Member
Site Search
News from the Field
Blog Home All Blogs
Search all posts for:   

 

View all (23) posts »
 

News from the Field: August 2016

Posted By Connections Editor, Friday, August 19, 2016

US grants for zebrafish studies on the rise
Zebrafish are the rising stars of model-organism research, an analysis of grants from the US National Institutes of Health (NIH) shows. A team at the NIH Office of Portfolio Analysis assessed trends in the agency’s funding of model-organism research between 2008 and 2015, through its R01 awards, the largest NIH grant program for individual investigators. [Nature]  

 

The Bulk of the Hematopoietic Stem Cell Population Is Dispensable for Murine Steady-State and Stress Hematopoiesis
Scientists depleted hematopoietic stem and progenitor cells in adult mice in situ and found that long term repopulating hematopoietic stem cells recovered from initially very low levels to below 10% of normal numbers but not more, while progenitor cells substantially recovered shortly after depletion. [Blood]

Increased Hematopoietic Activity in Patients with Atherosclerosis

Considering the chronic low-grade inflammatory state in atherosclerosis, the authors hypothesized that hematopoietic hyperactivity is a persistent feature in cardiovascular disease. They aimed to assess the activity of hematopoietic organs and hematopoietic stem and progenitor cells in humans. [Eur Heart J]

Kiadis Pharma’s Orphan Drug Designation for ATIR101™ Further Expanded to Include Treatment in a Hematopoietic Stem Cell Transplantation

Kiadis Pharma N.V. announced that its lead product, ATIR101™, has been granted an expansion to its existing Orphan Drug Designation by the European Medicines Agency to include treatment in a hematopoietic stem cell transplantation. [Kiadis Pharma N.V.]

Actinium Pharmaceuticals Initiates Pivotal Phase III SIERRA Trial

Actinium Pharmaceuticals, Inc. announced that the pivotal Phase III clinical trial for Iomab-B has been initiated. Iomab-B upon approval, is intended to be an induction and conditioning agent used to prepare patients with relapsed or refractory AML who are over the age of 55 for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. [Actinium Pharmaceuticals, Inc.]

This post has not been tagged.

Share |
Permalink | Comments (0)
 
Association Management Software Powered by YourMembership  ::  Legal